Free shipping on all orders over $ 500


Cat. No. M1752
MLN8237 Structure


Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 120 In stock
50mg USD 400 In stock
100mg USD 600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

MLN82379 (Alisertib) is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. MLN8237 (Alisertib) binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.

Product Citations
Customer Product Validations & Biological Datas
Source Journal of Hematology & Oncology (2017). Figure 7. MLN8237 (Abmole Bioscience)
Method CCK8 assay
Cell Lines U251, U87 and U118 cell lines
Incubation Time 48 h
Results Treatment with two other aurora kinase inhibitors, AZD1152 and MLN8237, demonstrated similar results (Fig. 7d).
Cell Experiment
Cell lines HCT-116, SW480, DLD-1, H460, MDA-MB-231, PC3, SKOV3 cell lines
Preparation method BrdU in vitro cell proliferation assay Thirteen tumor cell lines treated with increasing concentrations of alisertib over 96 hours were subjected to 5-bromo-2-deoxyuridine (BrdU) incorporation as a measurement of cellular proliferation. Proliferation of each cell line was measured using the cell proliferation ELISA, BrdU colorimetric kit according to the manufacturer's recommendations (Roche).
Concentrations 0~1µM
Incubation time 96h
Animal Experiment
Animal models Mice bearing the disseminated, CD20-positive, non-Hodgkin's lymphoma model OCI-LY19
Formulation 10% 2-hydroxypropyl-β-cyclodextrin and 1% sodium bicarbonate
Dosages 20 mg/kg twice daily or 30 mg/kg once daily
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 518.92
Formula C27H20ClFN4O4
CAS Number 1028486-01-2
Purity 99.71%
Solubility DMSO
Storage at -20°C

Pediatric Phase 1 Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase 1 Consortium study.
Mosse YP et al. Clin Cancer Res. 2012 Sep 17. PMID: 22988055.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Matulonis UA et al. Gynecol Oncol. 2012 Oct;127(1):63-9. PMID: 22772063.

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations.
Dees EC et al. Clin Cancer Res. 2012 Sep 11;18(17):4775-84. PMID: 22767670.

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Cervantes A et al. Clin Cancer Res. 2012 Sep 1;18(17):4764-74. PMID: 22753585.

Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines.
Muscal JA et al. Invest New Drugs. 2012 Jun 6. PMID: 22669335.

Related Aurora Kinase Products

SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively.


GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM. It displays >100-fold selectivity against the closely related Aurora A-TPX2 complex.


PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3.


MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity.


PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1.

Abmole Inhibitor Catalog 2017

Keywords: MLN8237, Alisertib supplier, Aurora Kinase, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.